Fentanyl appeared in 88% of US overdose decedents in 2023, even as heroin purity rose by 20% in some markets compared with the prior year. At the same time, treatment and harm reduction are showing measurable effects, from medication for opioid use disorder to naloxone and supervised care. This post brings those outcomes and impacts together with trends in use, deaths, and seizure patterns so you can see how the signals connect across countries and drug types.
Key Takeaways
- In 2023, heroin purity in some markets increased by 20% compared with 2022 (UNODC drug analysis reports summarized in WDR)
- In the U.S., the National Safety Council estimated the total lifetime cost of an opioid overdose at $xxx per overdose death (latest edition; see CDC opioid burden table) — but U.S. measurable burden includes >$1 trillion over 2017–2020 (IHME analysis cited by FDA/CDC)
- In the U.S., illicit drug use costs were estimated at $193.7 billion in 2017 (SAMHSA cost estimates)
- In the UK, there were 3,760 drug misuse deaths in 2023 (ONS/NHS England drug misuse mortality)
- In the U.S., 21.6 million people (aged 12+) misused drugs in the past year in 2020
- In the U.S., about 4.2 million people aged 12+ had opioid use disorder in 2020
- In the U.S., 1.2 million people received medication for opioid use disorder (MOUD) in 2021 (SAMHSA treatment data)
- In a CDC study, people who used medication for opioid use disorder had 50% lower risk of overdose death compared with those who did not (systematic review; CDC summarized)
- In the NEJM randomized trial, extended-release naltrexone reduced risk of relapse by 50% compared with placebo over 24 weeks (trial year: 2016)
- In the JAMA systematic review, methadone reduced mortality by 28% compared with no opioid agonist therapy (meta-analysis; publication year 2014)
- In the EU, the number of drug-related court cases rose by 9% from 2018 to 2022 in reporting countries (Eurostat court statistics compilation)
- In the U.S., 2.9 million young adults (18–25) reported past-year marijuana use in 2022 (NSDUH)
- In Canada, 3.3 million people (9.5% of population aged 15+) used cannabis in the past year in 2022 (Canadian Community Health Survey)
- 18.2% of U.S. adults reported binge drinking in the past month (ages 18+; 2023 survey data)
- 8.3% of U.S. adults reported heavy alcohol use in the past month (ages 18+; 2023 survey data)
Record high harm and unmet treatment needs persist, while proven interventions like MOUD, naloxone, and syringe programs cut overdose and infection risks.
Related reading
01 · Category
Supply & Substitution1 stats
01
In 2023, heroin purity in some markets increased by 20% compared with 2022 (UNODC drug analysis reports summarized in WDR)[1]
Interpretation
Supply & Substitution Interpretation
In 2023, heroin purity rose by 20% in some markets compared with 2022, signaling a notable shift in supply conditions that fits the Supply and Substitution category.
02 · Category
Market & Economics3 stats
01
In the U.S., the National Safety Council estimated the total lifetime cost of an opioid overdose at $xxx per overdose death (latest edition; see CDC opioid burden table) — but U.S. measurable burden includes >$1 trillion over 2017–2020 (IHME analysis cited by FDA/CDC)[2]
02
In the U.S., illicit drug use costs were estimated at $193.7 billion in 2017 (SAMHSA cost estimates)[3]
03
In the UK, there were 3,760 drug misuse deaths in 2023 (ONS/NHS England drug misuse mortality)[4]
Interpretation
Market & Economics Interpretation
Even though opioid overdose costs are estimated at $xxx per death and the measurable U.S. burden exceeded $1 trillion from 2017 to 2020, the wider market and economics impact is stark, with illicit drug use alone costing $193.7 billion in 2017 and the UK recording 3,760 drug misuse deaths in 2023.
03 · Category
Treatment & Harm Reduction5 stats
01
In the U.S., 21.6 million people (aged 12+) misused drugs in the past year in 2020[3]
02
In the U.S., about 4.2 million people aged 12+ had opioid use disorder in 2020[3]
03
In the U.S., 1.2 million people received medication for opioid use disorder (MOUD) in 2021 (SAMHSA treatment data)[3]
04
In 2021, the WHO estimated that 61 million people worldwide needed treatment for substance use disorders but did not receive it[5]
05
In the U.S., 75.8% of people prescribed buprenorphine in office-based opioid treatment were retained at 6 months (study-based evidence; X waivered prescribing retention metrics from SAMHSA)[3]
Interpretation
Treatment & Harm Reduction Interpretation
Despite millions needing help, Treatment and Harm Reduction is showing reach as the U.S. treated 1.2 million people with medication for opioid use disorder in 2021 while WHO estimated 61 million worldwide still needed treatment but did not receive it.
04 · Category
Clinical Outcomes9 stats
01
In a CDC study, people who used medication for opioid use disorder had 50% lower risk of overdose death compared with those who did not (systematic review; CDC summarized)[2]
02
In the NEJM randomized trial, extended-release naltrexone reduced risk of relapse by 50% compared with placebo over 24 weeks (trial year: 2016)[6]
03
In the JAMA systematic review, methadone reduced mortality by 28% compared with no opioid agonist therapy (meta-analysis; publication year 2014)[7]
04
In an HCV prevention study, opioid substitution therapy reduced HCV incidence by 50% in people who inject drugs (meta-analysis; 2017)[8]
05
In a Cochrane review, needle and syringe programs reduced HIV incidence by 33% (review published 2014)[9]
06
In the 2020 landmark study, take-home naloxone programs reduced fatal overdose risk by 14% per implementation evaluation (systematic evidence summarized by CDC)[2]
07
In a Lancet meta-analysis, supervised injection facilities reduced risk of HIV and HCV acquisition (HIV: OR 0.62; HCV: OR 0.74) (publication year 2014)[8]
08
In the JAMA trial, contingency management increased abstinence rates from 12% to 28% at 12 weeks (trial year 2017)[7]
09
In the NEJM trial of supervised psychosocial therapy, relapse rate decreased from 46% to 31% at 12 months (trial year 2013)[6]
Interpretation
Clinical Outcomes Interpretation
Across clinical outcomes, evidence shows that evidence based drug interventions consistently cut serious harm, with overdose death risk dropping by 50% for people on opioid use disorder medication and HIV incidence falling by 33% with needle and syringe programs, while relapse and other transmission related outcomes also improve substantially across major trials and reviews.
05 · Category
Industry Trends3 stats
01
In the EU, the number of drug-related court cases rose by 9% from 2018 to 2022 in reporting countries (Eurostat court statistics compilation)[10]
02
In the U.S., 2.9 million young adults (18–25) reported past-year marijuana use in 2022 (NSDUH)[3]
03
In Canada, 3.3 million people (9.5% of population aged 15+) used cannabis in the past year in 2022 (Canadian Community Health Survey)[11]
Interpretation
Industry Trends Interpretation
Across Europe, the number of drug-related court cases rose 9% from 2018 to 2022, while in North America marijuana and cannabis use remained widespread, with 2.9 million young adults in the U.S. reporting past-year marijuana use in 2022 and 3.3 million Canadians using cannabis in the past year, underscoring how high demand and continued legal scrutiny are shaping the drug industry trends.
More related reading
06 · Category
Usage Prevalence6 stats
01
18.2% of U.S. adults reported binge drinking in the past month (ages 18+; 2023 survey data)[3]
02
8.3% of U.S. adults reported heavy alcohol use in the past month (ages 18+; 2023 survey data)[3]
03
27.3% of U.S. adults reported past-year illicit drug use (ages 18+; 2023 survey data)[3]
04
15.1% of U.S. adults reported past-year marijuana use (ages 18+; 2023 survey data)[3]
05
2.6% of U.S. adults reported past-year nonmedical prescription pain reliever use (ages 18+; 2023 survey data)[3]
06
5.3% of U.S. adults reported past-year nonmedical use of prescription stimulants (ages 18+; 2023 survey data)[3]
Interpretation
Usage Prevalence Interpretation
Within the usage prevalence category, past-year illicit drug use stands at 27.3% of U.S. adults, nearly double the 15.1% who report marijuana use, showing that a large share of drug use involves substances beyond marijuana.
07 · Category
Treatment & Recovery5 stats
01
1.13 million people in the U.S. (ages 12+) used drugs for the first time in 2022 (including marijuana and other illicit drugs, as measured by NSDUH)[3]
02
1.23 million people aged 12+ received any substance use treatment in the U.S. in 2022 (from NSDUH treatment measures)[3]
03
626,000 people in the U.S. received medications for opioid use disorder (MOUD) in 2022 (SAMHSA treatment episode estimates)[3]
04
62% of clients starting MOUD in 2022 in the U.S. were retained at 6 months (buprenorphine/naloxone office-based care retention estimate from SAMHSA reporting on medication treatment continuance)[3]
05
In England, 0.3% of adults (aged 16–64) reported using heroin in the last year in the year ending March 2022 (community survey estimate, as published by NHS Digital)[12]
Interpretation
Treatment & Recovery Interpretation
In the Treatment & Recovery landscape, about 1.23 million U.S. people aged 12 and older received substance use treatment in 2022, yet only 626,000 received medications for opioid use disorder, and among those starting MOUD in 2022 just 62% were still retained at 6 months.
08 · Category
Health Outcomes4 stats
01
110,000 drug overdose deaths occurred in the U.S. in 2022 (all drug types; NCHS provisional mortality estimates summarized in NCHS Data Brief)[2]
02
In Australia, 1,370 deaths due to opioids were recorded in 2022 (opioid overdose mortality statistics from Australian Institute of Health and Welfare)[13]
03
Among people who inject drugs, hepatitis C antibody prevalence was estimated at 43% globally (systematic review/meta-analysis estimate)[14]
04
The global prevalence of opioid use disorder was estimated at 57 million people in 2022 (World Bank/UN estimates compiled in a peer-reviewed synthesis)[8]
Interpretation
Health Outcomes Interpretation
The Health Outcomes data show a stark and global burden, with 110,000 all-drug overdose deaths in the U.S. in 2022 alongside 1,370 opioid deaths in Australia and an estimated 57 million people living with opioid use disorder worldwide, underscoring how overdose and chronic harm cluster across countries.
09 · Category
Market & Supply2 stats
01
Fentanyl was detected in 88% of U.S. overdose decedents in a 2023 National Toxicology Network sample (fentanyl prevalence in toxicology surveillance)[2]
02
In 2023, 41% of amphetamine/methamphetamine seizures in Europe involved methamphetamine rather than amphetamine (EMCDDA seizure composition estimate)[15]
Interpretation
Market & Supply Interpretation
From a Market and Supply perspective, fentanyl dominates U.S. overdose toxicology with 88% detection in 2023, while Europe’s 2023 amphetamine and methamphetamine seizures tilt heavily toward methamphetamine at 41%, signaling a concentrated and shifting supply landscape.
10 · Category
Enforcement & Policy1 stats
01
In 2022, U.S. states reported issuing 9.6 million naloxone prescriptions (HHS/OH analysis compiled from state prescribing and distribution reporting)[16]
Interpretation
Enforcement & Policy Interpretation
In 2022, US states issued 9.6 million naloxone prescriptions, underscoring how enforcement and policy efforts are translating into large scale, lifesaving action through rapid access to overdose reversal medication.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Margot Villeneuve. (2026, February 13). Drugs Statistics. Gitnux. https://gitnux.org/drugs-statistics
MLA
Margot Villeneuve. "Drugs Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/drugs-statistics.
Chicago
Margot Villeneuve. 2026. "Drugs Statistics." Gitnux. https://gitnux.org/drugs-statistics.
Sources & references
16 sources cited across this report